Stephen Gephardt, MD
Interventional Pain Medicine · Las Vegas, NVNPI 1154307635
Payments from drug & device makers
Across 616 payments — averaging $22.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$2K
- AbbVie$2K
- Abbott$1K
- Scilex Pharmaceuticals Inc.$925
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$814
- Boston Scientific$600
- plus $6K from 45 others
What the payments were for
- Food & beverage$13,873100%
- Gifts$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnia$553
- Senza$498
- Proclaim Family of SCS IPGs$307
- Senza II$281
- Senza Spinal Cord Stimulation System$199
- PROCLAIM$176
- GENERAL PAIN MANAGEMENT$172
- Proclaim IPG$171
- Nalu Neurostimulation System$148
- INTELLIS ADAPTIVESTIM$144
- KYPHON EXPRESS II KYPHOPAK TRAY$144
- Evoke$137
- iFuse Implant$128
- RELISTOR$125
- AIMOVIG$120
- QULIPTA$119
- VYEPTI$107
How this compares
$13,873 in reported general payments places this provider in the 70th percentile of 32 interventional pain medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine | 31 | $3,407 |
| Oxycodone Hcl | 125 | $2,827 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 74 | $2,588 |
| Morphine Sulfate ErMorphine Sulfate | 75 | $2,379 |
| Fentanyl | 22 | $1,940 |
| Gabapentin | 123 | $1,623 |
| Pregabalin | 58 | $1,515 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 62 | $1,416 |
| Naloxone Hcl | 20 | $1,178 |
| Diclofenac Sodium | 15 | $823 |
| Tramadol Hcl | 50 | $757 |
| Morphine Sulfate | 23 | $751 |
| Tizanidine Hcl | 87 | $734 |
| Modafinil | 13 | $517 |
| Methadone Hcl | 18 | $455 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Las Vegas
- Daniel BurkheadLas Vegas$29K
- Adam AntflickLas Vegas$26K
- Jeremy LipshutzLas Vegas$13K
- Denys GoloshchapovLas Vegas$11K
- Edson ErkulvrawatrLas Vegas$6K
- Alafuro OrueneLas Vegas$6K
- Dolue EzeanolueLas Vegas$5K
- Katherine TravnicekLas Vegas$5K
- Godwin MadukaLas Vegas$4K
- Haroon AndarLas Vegas$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.